A threshold of 570 U/L is associated with CAS risk, specifically in those with concurrent advanced liver fibrosis, highlighting the potential role of Lp-PLA2 in cardiovascular risk stratification in this subset but within the limitations of a cross-sectional study. The gene discussed is PLA2G7; the disease is Hepatic fibrosis.